Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
163 results about "Cancer targeting" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Targeted cancer therapies block specific proteins or genes that help cancers grow and spread. For some types of cancer, they may work better than other treatments like chemotherapy. The FDA has approved targeted therapies for more than 15 types of cancer, including those of the breast, prostate, colon, and lung.
Cancer stem cell expression patterns and compounds to target cancer stem cells
InactiveUS20110020221A1Inhibit progressPrevent worseningIn-vivo radioactive preparationsImmunoglobulins against cell receptors/antigens/surface-determinantsCancer targetingMolecular Targeted Therapies
Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.
Owner:THE JOHNS HOPKINA UNIV
Methods of cancer therapy targeted against a cancer stem line
InactiveUS7361336B1Preventing clinical relapseReduce the burden onOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAfter treatmentCancer targeting
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.
Owner:BERGSTEIN IVAN
Engineered Anti-Prostate Stem Cell Antigen (PSCA) Antibodies for Cancer Targeting
ActiveUS20090311181A1In-vivo radioactive preparationsAntibody mimetics/scaffoldsAntigenBladder cancer
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
Owner:RGT UNIV OF CALIFORNIA
Targeted innate immunity
InactiveUS20060135459A1Hybrid immunoglobulinsSugar derivativesAbnormal tissue growthCancer targeting
Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
Owner:UNIV OF SOUTHERN CALIFORNIA
Next generation sequencing-based detection panel and detection kit for pan-cancer targeting, chemotherapy and immune drugs and application thereof
ActiveCN109609647AReduce data volumeImprove uniformityMicrobiological testing/measurementGenes mutationCancer targeting
The invention discloses a next generation sequencing-based detection panel and detection kit for pan-cancer targeting, chemotherapy and immune drugs and application thereof. The detection panel includes gene mutations related to pan-cancer type, treatment and prognosis, tumor mutation load calculation related exon regions and microsatellite instability sites. According the technical solution of the present invention, the detection panel includes the gene mutations related to pan-cancer type, treatment and prognosis, the tumor mutation load calculation related exon regions and the microsatellite instability sites, and the gene information included is comprehensive; a variety of tumor mutations can be jointly detected; and the detection panel and detection kit can be used for the concomitantdiagnosis of targeted drugs, chemotherapeutics or immune drugs to obtain accurate results.
Owner:ZHENYUE BIOTECHNOLOGY JIANGSU CO LTD
Novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.
Owner:SUMITOMO DAINIPPON PHARMA ONCOLOGY INC
Methods for identification and use of agents targeting cancer stem cells
The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and / or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and / or survival of cancer stem cells in a subject in need thereof.
Owner:MASSACHUSETTS INST OF TECH +1
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
ActiveUS8940871B2Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenBladder cancer
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
Owner:RGT UNIV OF CALIFORNIA
P53 modulator and cancer target
Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and / or biological activity are described. In particular, methods of screening of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukaemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Treating cancer stem cells using targeted cargo proteins
InactiveUS20110171219A1Inhibiting growth of cellPeptide/protein ingredientsAntibody mimetics/scaffoldsMedicineCancer cell
Owner:MEDICENNA THERAPEUTICS
Plant anti-cancer targeting nano-preparation, and preparation method thereof
The invention discloses a plant anti-cancer targeting nano-preparation, and a preparation method of the nano-preparation. The nano-preparation comprises (by weight) 43-60% of human blood albumin, 1.5-7.5% of plant anti-cancer drug, 24-40% of hyaluronic acid with molecular weight of 3,000-1,800,000 Da, 3.5-15 % of nanoparticle stabilizer, and the balance of water. The preparation method includes preparation of hyaluronic acid-albumin conjugate; preparation of plant anti-cancer drug solution; and preparation of the targeting nano-preparation. The plant anti-cancer targeting nano-preparation has good stability and bio-targeting function.
Owner:AC PHARMA
Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
ActiveUS20050260212A1Useful in therapyAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthCancer targeting
Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head / neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
Owner:ABBVIE BIOTHERAPEUTICS
Small molecule ligand-drug conjugates for targeted cancer therapy
The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.
Owner:EMORY UNIVERSITY +1
Bicyclic peptide ligands specific for MT1-MMP
ActiveUS10532106B2Organic active ingredientsPeptide/protein ingredientsCyclic peptideCancer targeting
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups which have utility in imaging and targeted cancer therapy.
Owner:BICYCLERD LTD
Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and Anti-tumor compound
InactiveUS20110287036A1Improve anti-tumor effectEffectively exhibit antitumor effectImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCancer targetingTumor therapy
The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.
Owner:NAT CANCER CENT +1
Compositions and methods for targeting cancer stem cells
InactiveUS20190031780A1Reduce in quantityHeavy metal active ingredientsOrganic active ingredientsCancer targetingCombined treatment
Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
Owner:SEAGEN INC +1
Methylene blue nanoparticle for bioimaging and photodynamic therapy and use thereof
ActiveUS20150273084A1Raise the possibilityLower the thresholdUltrasonic/sonic/infrasonic diagnosticsLuminescence/biological staining preparationPhotodynamic therapyCancer targeting
The present invention relates to a methylene blue nanoparticle for bioimaging and photodynamic therapy, and a use thereof as a cancer therapeutic agent and a contrast agent. The methylene blue nanoparticle of the present invention for use as a topical cancer targeting photo therapeutic agent is composed of only a material of which the composition is clinically used or derived from human bodies, and thus a nanopreparation in which a barrier to clinical entry is low and the possibility of commercialization is very high, exhibits near-infrared fluorescence along with cancer targeting property, capacity of generating singlet oxygen and the like, and thus may be used for both bioimaging diagnosis such as optical imaging, and cancer targeting photodynamic therapy.
Owner:D R NANO CO LTD
Novel compounds and compositions for targeting cancer stem cells
InactiveUS20130034591A1Reduce the temperatureMore brittlePowder deliveryBiocideCancer cellOrganic chemistry
Owner:BOSTON BIOMEDICAL
Multi-Modal Imaging for Diagnosis of Early Stage Epithelial Cancers
InactiveUS20120101390A1Increase contrastEnhanced contrast fluorescence imageUltrasonic/sonic/infrasonic diagnosticsPowder deliveryCancer targetingCancers diagnosis
Epithelial cancer screening can include a staining tissue with a cancer targeting agent, identifying a potentially cancerous lesion using fluorescence imaging, and imaging the potentially cancerous lesion for a cancer diagnosis using optical coherence tomography.
Owner:PHYSICAL SCI
Phthalocyanine compound, preparation method and application as single/two-photon fluorescent probe in cancer targeting and mitochondria labeling
ActiveCN104861039AHigh affinityOvercome phototoxicityMicrobiological testing/measurementLuminescent compositionsCancer targetingFluorescence
The invention relates to a phthalocyanine compound, a preparation method and an application as a single / two-photon fluorescent probe in cancer targeting and mitochondria labeling. The phthalocyanine compound has a structure of formula (I) and is an asymmetric phthalocyanine metal complex; R represents a polypeptide containing an RGD sequence, n is 0-6; the phthalocyanine compound not only has unique selectivity for cancer cells, but also can realize specific localization in live cell mitochondria, and is a multifunctional fluorescent probe. The invention also provides the preparation method of the phthalocyanine compound, wherein the preparation method is simple in process and wide in application range. The phthalocyanine compound overcomes the common phototoxicity of phthalocyanine; under 12 J / cm<2> of red light irradiation energy, the survival rate of cells is above 95%; and the phthalocyanine compound has good application value in two-photon tumor imaging and mitochondria imaging.
Owner:SHANDONG UNIV
Method to inhibit cancer targeting cd24
ActiveUS20100166649A1Easy to killPrevent cancerCompounds screening/testingIn-vivo radioactive preparationsP-selectinCancer targeting
The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
Owner:ABION CORP CO LTD
Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
ActiveUS20140335018A1Synergistic effectEfficient killingUltrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsLymphatic SpreadCancer targeting
The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
Owner:VISION GLOBAL HLDG
Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein
ActiveCN102391377ACancer targetingGood killing effectBacteriaPeptide/protein ingredientsCancer targetingVascular endothelium
The invention discloses a fusion protein capable of inducing and activating cancer targeting T-cells as well as a preparation method and application of the fusion protein. The fusion protein contains peptide acting with cancer cells as well as costimulatory molecules B7.1, wherein the peptide acting with the cancer cells is selected from a transforming growth factor-alpha, an epidermal growth factor, a vascular endothelial growth factor, gonadotropinreleasing hormone or gastrin-releasing peptide. The fusion protein has a targeting function; the fusion protein can act with VEGFR, EGFR, GnRH-R, or GRP-R respectively on one hand and interact with corresponding receptors CD28 and CTLA-4 expressed on the T-cells, therefore the targeting of the T-cells is positioned at the periphery of the cancer cells greatly expressing VEGFR, EGFR, GnRH-R, or GRP-R. Proven by experiments, the fusion protein can restrain the growth of tumors and cause cancer cells to apoptosis.
Owner:孙嘉琳 +1
Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
ActiveUS20140255377A1Efficiently depletedHigh activityHydrolasesPeptide/protein ingredientsDiseaseHalf-life
The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U / mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and / or inhibiting metastasis.
Owner:VISION GLOBAL HLDG
Phospholipid ether analogs as cancer-targeting drug vehicles
ActiveUS9345718B1Organic active ingredientsGroup 5/15 element organic compoundsCancer targetingMedicine
Owner:CELLECTAR BIOSCI
Novel application of magnetic Prussian blue nanoparticles to cancer targeting diagnosis and treatment
InactiveCN104096244AHigh relaxation rateStrong targetingEnergy modified materialsNMR/MRI constrast preparationsCancer targetingIn vivo
The invention relates to development of novel application of existing magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer. Magnetic Prussian blue is a traditional nano material and mainly comprises ferroferric oxide nano cores and Prussian blue nano shells. Prussian blue is an efficient near infrared light heat agent, and a clinical medicine with high biological safety in vivo. Ferroferric oxide has good magnetic resonance imaging and magnetic targeting effects, and has also been applied to the clinic. The existing preparation method of magnetic Prussian blue nanoparticles is mature, simple, green and low in cost. The invention develops novel application of magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer, achieves the integration of utilization of the magnetic Prussian blue nanoparticles to targeting diagnosis and treatment for cancer, and has extremely broad application prospect in diagnosis and treatment of cancer.
Owner:PEKING UNIV
Beta-carboline-cycloenone derivative based on dual response to pH value and GSH and application thereof
ActiveCN110981870AEnhanced anti-tumor proliferationHigh activityOrganic chemistryFluorescence/phosphorescenceCancer targetingDual response
The invention discloses a beta-carboline-cycloenone derivative with a structure as shown in a general formula which is described in the specification. According to the invention, an electron-donatinggroup is introduced into a proper part of beta-carboline, and the 3-site amino group of beta-carboline is connected with cycloenone having anti-tumor activity by utilizing a carbamate bond, so the novel beta-carboline-cycloenone derivative is designed and synthesized. The derivative realizes pH and GSH dual-response fluorescence imaging and diagnosis in a tumor microenvironment, and can selectively target to GSTpi highly-expressed in tumor tissue, so tumor cell proliferation can be significantly inhibited. Such a pH / GSH dual-response fluorescence and cancer-targeting treatment diagnosis and treatment drug provides a new choice for accurate diagnosis and targeting treatment of tumors, and broadens the application of multifunctional molecules in accurate medical treatment.
Owner:NANTONG UNIVERSITY
Cancer-targeting recombinant oncolytic gene-adenovirus and construction method and application thereof
ActiveCN108342366AAchieve successful interferenceLow toxicityMicroorganism based processesFermentationCancer targetingRate limiting enzyme
The present invention discloses a group of cancer-targeting recombinant oncolytic gene-adenovirus, comprising OncoAd, OncoAd. RGD, and OncoAd. RGD. shPKM2. The invention also discloses a constructionmethod and application of the recombinant oncolytic gene-adenovirus OncoAd. RGD. shPKM2 in preparing of a medicine for treating pancreatic cancer. The recombinant oncolytic gene-adenovirus OncoAd. RGD. shPKM2 can achieves silencing of expression of rate-limiting enzyme gene PKM2 by means of replication of an adenoviral vector, and can play an effective pancreatic cancer killing effect.
Owner:SHANGHAI YUANSONG BIOTECHNOLOGY CO LTD
Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
InactiveUS20150343079A1Increase capacityMaximizing therapeutic efficacyUltrasonic/sonic/infrasonic diagnosticsPowder deliveryCavitationCancer targeting
The present invention relates to an ultrasound contrast agent with drug-encapsulating nanoparticles and a method for preparing the same that increase drug delivery capabilities and drug penetration effects. According to the present invention, exposure to the focussed ultrasound triggers the cavitation of an ultrasound contrast agent, resulting in the local release of drug-encapsulating nanoparticles, which are conjugated onto the surface of the ultrasound contrast agent, and enhanced penetration of nanoparticles and drug delivery capabilities. Moreover, the present invention simultaneously and selectively diagnoses and treats cancers by conjugation cancer-targeting ligands on the surface of nanoparticles.
Owner:IMGT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com